At a glance
- Originator LEO Pharma
- Developer AstraZeneca; LEO Pharma
- Class Anti-ischaemics; Antiarrhythmics; Antihypertensives; Guanidines; Muscle relaxants; Vasodilators
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alopecia; Arrhythmias; Ischaemic heart disorders
Most Recent Events
- 03 Nov 2000 Discontinued-II for Alopecia in Europe (Unknown route)
- 03 Nov 2000 Discontinued-Preclinical for Arrhythmias in Sweden (Unknown route)
- 03 Nov 2000 Discontinued-Preclinical for Ischaemic heart disorders in Sweden (Unknown route)